Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer

Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer

Selpercatinib, a RET kinase inhibitor, is an effective treatment for patients with medullary thyroid cancer with RET mutations. In this paper, we present the case of a 62-year-old man with ectopic Cushing’s syndrome due to medullary thyroid cancer who received treatment with selpercatinib. Six month...

Full description

Bibliographic Details
Main Authors: Oskar Ragnarsson, Marta Piasecka, Andreas Hallqvist
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Current Oncology
Subjects:
medullary thyroid cancer
ectopic Cushing’s syndrome
paraneoplastic syndrome
hypercortisolism
Online Access:https://www.mdpi.com/1718-7729/29/5/282

Similar Items

Similar Items